“Genomic Catastrophe” May Cause Normal Cells to Become Cancerous
Aberrant Cell Fusion May Initiate
Cancerous Processes and Tumor Formation, According to a New Study Published in
The American Journal of Pathology
Although there is no one established universal cause of cancer, genetic changes are central to its development. The accumulation of spontaneous genetic changes, or mutations, that occur when cells divide can be hastened by exposure to carcinogens such as cigarette smoke (lung cancer) and infectious agents such as the papillomavirus (cervical cancer). However, some researchers believe that spontaneous mutations are too infrequent, and the link between carcinogens and genetic changes too uncertain, to fully explain the development of some of the most common cancers. The results of this study may provide an explanation: that fusion of one normal cell with another — as observed in inflammation, infection, and injury from carcinogens — triggers a “genomic catastrophe” that convertsnormal cells to cancer cells and enables tumors to form.
Cell fusion is a process in which one or more cells combine to form a new cell with more than one nucleus. Cell fusion has been postulated as a possible cause for some cancers because it could explain the occurrence of multiple genetic changes thought to underlie cancer. However, direct evidence that fusion of normal cells by itself could trigger cancer has not been reported. Now, a new study published in The American Journal of Pathology provides the missing link between a single untoward event, cell fusion, and the multiple catastrophic genetic changes that ultimately transform normal cells into cancerous cells. Furthermore, when injected into live animals, these aberrant cells form tumors.
Researchers from the University of Michigan and the Mayo Clinic studied rat IEC-6 intestinal epithelial cells, chosen because they maintain a stable diploid genomic structure (two sets of chromosomes), lack the cellular characteristics of cancer cells, and replicate normally. They also do not form tumors when monitored over many generations. IEC-6 cells were labeled with either red or green fluorescent dyes. The cells were then exposed to 50% polyethylene glycol to encourage cell fusion. The fused cells were identified by the presence of both red and green dyes within one cell, whereas nonfused cells displayed only one color. Fused cells were also larger than non-fused cells.
Caption: Typical image of fused cell sorted by FACS and visualized by fluorescence microscopy. The fused cell emits both CFSE (green) and SNARF-1 (red) fluorescence; the image represents at least 50 cells examined per experiment. Scale Bar: 5 µm
Investigators made several important observations. First, they showed that fused cells could replicate, with 19% of fused IEC-6 cells establishing clones and that with replication the chromosomes from the two cells intermixed. They also observed that 41% of the clones had abnormal numbers of chromosomes (aneuploidy), 56% were near-diploid (40 to 44 chromosomes), and 4% were tetraploid (84 chromosomes), whereas the large majority (86%) of non-fused cells were diploid. “These results indicate that cell fusion generates chromosomal instability,” explained lead investigator Jeffrey L. Platt, MD, Professor of Surgery and Microbiology and Immunology, Departments of Microbiology and Immunology and Surgery, University of Michigan (Ann Arbor). Chromosomal instability refers to changes in the number and appearance of chromosomes in a species.
Because aneuploidy and chromosomal abnormalities are commonly observed in cancer, the researchers looked for evidence of DNA damage in the fused clones. The double-strand DNA break marker phosphorylated Ɣ-H2AX revealed breaks in significantly more fusion-derived clones than in nonfused clones (35% to 42% versus 4% to 9%, P < 0.0001). This finding suggests that after cells fuse, chromosomal instability might lead to DNA damage and hence to genetic changes that underlie cancer. Consistent with that possibility, fused cells often exhibited the same abnormal growth characteristics as cancer cells.
“The frequency of cell fusion events in vivo is not known, although cell fusion is thought to occur under some circumstances such as cell injury, inflammation, and viral infection. Although fusion of normal cells in vitro and in vivo may be a rare event, this study shows that cell fusion between normal cells can have pathological consequences,” commented noted authority and cancer specialist William B. Coleman, PhD, of the Department of Pathology and Laboratory Medicine, Program in Translational Medicine at the University of North Carolina Comprehensive Cancer Center (Chapel Hill). “The results provide evidence for another molecular mechanism driving neoplastic transformation – genomic catastrophe.”
Perhaps the most exciting observation occurred when fused IEC-6 cells were transplanted into immunodeficient mice. Over the course of 12 weeks, these cells generated tumors in 61% (11/18) of the hosts whereas no tumors formed from the parental IEC-6 cells or IEC-6 cells that did not fuse. Furthermore, only those fusion-derived IEC-6 cell clones that had undergone the changes in cellular growth indicative of neoplastic transformation produced tumors in mice. “We believe one cell fusion event can both initiate malignancy and fuel evolution of the tumor that ensues,” noted lead author Xiaofeng Zhou, Department of Microbiology and Immunology and Surgery and the Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, at the University of Michigan (Ann Arbor).
According to Dr. Coleman, most cases of spontaneous cancers in humans are thought to derive from cells that sustained random DNA damage or random errors during DNA replication. “Zhou et al provide evidence for a different mechanism of spontaneous neoplastic transformation. The observations suggest strongly that genomic catastrophe can produce the required and necessary molecular alterations for neoplastic transformation and tumorigenesis in normal founder cells in the absence of selective pressures or ongoing genomic evolution.” Dr. Coleman added that further research is needed to determine whether cell fusion events between normal human cell types result in genomic catastrophe and neoplastic transformation.
“Cell Fusion Connects Oncogenesis with Tumor Evolution,” by Xiaofeng Zhou, Kevin Merchak, Woojin Lee, Joseph P. Grande, Marilia Cascalho, and Jeffrey L. Platt (DOI: http://dx.doi.org/10.1016/j.ajpath.2015.03.014). This article appears online ahead of The American Journal of Pathology, Volume 185, Issue 7 (July 2015) published by Elsevier.
The study is supported by NIH grants HL52297 and T32HL007749 and the University of Michigan Comprehensive Cancer Center.
Full text of this study is available to credentialed journalists upon request; contact Eileen Leahy at +1 732-238-3628 or firstname.lastname@example.org. Journalists wishing to interview the authors should contact Jeffrey L. Platt at +1 734-615-7755 or email@example.com. William B. Coleman may be contacted at +1 919-966-2699 or firstname.lastname@example.org.
American Journal of Pathology
The American Journal of Pathology (http://ajp.amjpathol.org), official journal of the American Society for Investigative Pathology, seeks to publish high-quality, original papers on the cellular and molecular biology of disease. The editors accept manuscripts that advance basic and translational knowledge of the pathogenesis, classification, diagnosis, and mechanisms of disease, without preference for a specific analytic method. High priority is given to studies on human disease and relevant experimental models using cellular, molecular, animal, biological, chemical, and immunological approaches in conjunction with morphology.
The leading global forum for reporting quality original research on cellular and molecular mechanisms of disease, The American Journal of Pathology is the most highly cited journal in Pathology – over 39,000 cites in 2013 – with an Impact Factor of 4.602 and Eigenfactor of 0.07076 according to the 2013 Journal Citation Reports®, Thomson Reuters, and an h-index of 206 according to the 2013 SCImago Journal and Country Rank.
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Research Intelligence and ClinicalKey— and publishes over 2,500 journals, including The Lancet and Cell, and more than 35,000 book titles, including a number of iconic reference works. Elsevier is part of RELX Group, a world-leading provider of information and analytics for professional and business customers across industries. www.elsevier.com